Myocardial preservation: a comparison of oxygenated crystalloid and blood cardioplegia.
The purpose of this experiment was to compare myocardial protective effect after global ischemia using oxygenated crystalloid (CCcO2) and an oxygenated blood (BCcO2) cardioplegic solutions. Post-ischemic ventricular performance was studied in 2 equal (n = 7) groups of dogs subjected to 120 min of global ischemia induced at average myocardial temperatures of 8 degrees C in the CCcO2 group and 18 degrees C in the BCcO2 group. Left ventricular (LV) function included analysis of LV systolic function (global and regional function), LV diastolic function (chamber and myocardial stiffness) and LV relaxation was measured by sonomicrometry and Millar micrometers. Data were processed with a Dec PDP-11/23 computer. In vitro oxygen content (Vol%) measured 3.2 +/- 1.0 (CCcO2) and 9.5 +/- 0.3 (BCcO2). Percent recoveries of LV global function (LVSP, loop area, % shortening, LV dp/dt, mean VCF and E max) in the CCcO2 group were approximately the same as those in the BCcO2 group. There were no significant differences in LV regional function (loop area and % shortening) after ischemia between the two groups. The chamber and myocardial stiffness after ischemia in the CCcO2 group were almost the same as the baseline values. Values in the BCcO2 group were reduced significantly compared to the baseline level. There were significant differences in post-ischemic chamber and myocardial stiffness between the two groups. Post-ischemic maximum negative LV dp/dt in both groups decreased significantly compared to the baseline values. However, the time constant and diastolic interval after ischemia in both groups were approximately the same as the baseline values. We conclude that there were no significant differences in myocardial protective effect between the CCcO2 and BCcO2 groups, and both methods preserved the ischemic myocardium well.
Tabayashi
K
K
Department of Thoracic and Cardiovascular Surgery, Tohoku University School of Medicine, Sendai.
McKeown
P P
PP
Miyamoto
M
M
Luedtke
A E
AE
Thomas
R
R
Breazeale
D G
DG
Misbach
G A
GA
Allen
M
M
Ivey
T D
TD
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002314:Cardioplegic Solutions / Q000494:pharmacology*; D003327:Coronary Disease / Q000503:physiopathology*; D000077324:Crystalloid Solutions; D004285:Dogs; D004554:Electric Countershock; D004562:Electrocardiography; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D066298:In Vitro Techniques; D007552:Isotonic Solutions; D010952:Plasma Substitutes / Q000494:pharmacology*; D013696:Temperature; D014021:Tissue Preservation
D002314:Cardioplegic Solutions; D000077324:Crystalloid Solutions; D007552:Isotonic Solutions; D010952:Plasma Substitutes